Benchmark Reiterates “Hold” Rating for VolitionRx (NYSE:VNRX)

Benchmark reaffirmed their hold rating on shares of VolitionRx (NYSE:VNRX) in a research note released on Friday morning,Benzinga reports.

Separately, StockNews.com started coverage on shares of VolitionRx in a report on Wednesday. They set a “sell” rating for the company.

VolitionRx Trading Down 0.8 %

Shares of VolitionRx stock opened at $0.80 on Friday. The firm’s 50-day simple moving average is $0.69 and its 200-day simple moving average is $0.68. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC grew its stake in VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.